BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36676701)

  • 21. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
    Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
    Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
    Shimazu Y; Nohgawa M
    J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
    [No Abstract]   [Full Text] [Related]  

  • 25. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Abramson JS
    Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The unexpected evolution of a case of diffuse large B-cell non-Hodgkin lymphoma.
    Găman A; Bold A; Găman G
    Rom J Morphol Embryol; 2011; 52(2):719-22. PubMed ID: 21655667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
    Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
    Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
    Deng L; Song Y; Zhu J; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Liu W; Zhang C
    Int J Hematol; 2013 Dec; 98(6):664-71. PubMed ID: 24234713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Rare Case of Diffuse Large B Cell Lymphoma Presenting as a Cardiac Mass.
    Yousif P; Kotecha A; Thakur A; Ismail HM
    Am J Case Rep; 2019 Dec; 20():1821-1825. PubMed ID: 31809493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
    Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
    J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.
    Masir N; Akhter A; Roshan TM; Florence CS; Abdul-Rahman F; Tumian NR; Kean-Chang P; Elyamany G; Shabani-Rad MT; Mansoor A
    J Clin Pathol; 2019 Sep; 72(9):630-635. PubMed ID: 31189540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
    Huang HH; Hsiao FY; Chen HM; Wang CY; Ko BS
    Br J Haematol; 2021 Jan; 192(1):110-118. PubMed ID: 33131074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
    Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetics and diffuse large B-Cell lymphoma.
    Niroula R; Butera J
    R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
    Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
    Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.